The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin-1

International Journal of Cardiology

Volumn 72, Issue 2, 2000, Pages 175-186

  Sharma, Rakesh ^a   Coats, Andrew J S ^a   Anker, Stefan D ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMRINONE; ANTIOXIDANT; AUTOANTIBODY; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; FREE RADICAL; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; METALLOPROTEINASE; NITRIC OXIDE; OXYGEN RADICAL; PADGEM PROTEIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

CELL INTERACTION; CYTOTOXICITY; HEART FAILURE; HUMAN; IMMUNE RESPONSE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0033963673     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(99)00186-2     Document Type: Article

References (121)

1. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Flohr K.H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 314:1986;1547-1552.
2. Anker S.D., Coats A.J.S. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 115:1999;836-847.
3. Shan K., Kurrelmeyer K., Seta Y., Wang F., Dibbs Z., Deswal A., Lee-Jackson D., Mann D.L. The role of cytokines in disease progression in heart failure. Current Opinion in Cardiology. 12:1997;218-223.
4. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 72:1975;3666-3670.
5. Levine B., Kalman J., Mayer L., Fillit H., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
6. Anker S.D., Clark A.L., Kemp M., Salsbury C., Teixeira M.M., Hellewell P.G., Coats A.J. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 30:1997;997-1001.
7. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., Mann D.L. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
8. Suffredini A.F., Fromm R.E., Parker M.M., Brenner M., Kovacs J.A., Wesley R.A., Parrillo J.E. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 321:1989;280-287.
9. Torre-Amione G., Kapadia S., Lee J., Bies R.D., Lebovitz R., Mann D.L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487-1493.
10. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., Harrington D., Kox W.J., Poole-Wilson P.A., Coats A.J. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 349:1997;1050-1053.
11. Anker S.D., Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Current Opinion in Cardiology. 14:1999;211-216.
12. Anker S.D., Chua T.P., Ponikowski P., Harrington D., Swan J.W., Kox W.J., Poole-Wilson P.A., Coats A.J. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 96:1997;526-534.
13. Adams V., Jiang H., Jiangtao Y., Mobius-Winkler S., Fiehn E., Linke A., Weigl C., Schuler G., Hambrecht R. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 33:1999;959-965.
14. Tracey K.J., Morgello S., Koplin B., Fahey T.J., Fox K., Aledo A. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute cachexia. J Clin Invest. 86:1990;2014-2024.
15. Krown K.A., Page M.T., Nguyen C., Zechner D., Gutierrez V., Comstock K.L., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest. 98:1996;2854-2865.
16. Ferrari R., Bachetti T., Confortini R., Opasich C., Febo O., Corti A., Cassani G., Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
17. Anker S.D., Ponikowski P.P., Clark A.L., Leyva F., Rauchhaus M., Kemp M., Teixeira M.M., Hellewell P.G., Hooper J., Poole-Wilson P.A., Coats A.J. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 20:1999;683-693.
18. Dibbs Z., Thornby J., White B., Mann D. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 33:1999;1935-1942.
19. Francis S.E., Holden H., Holt C.M., Duff G.W. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 30:1998;215-223.
20. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757.
21. Munger M.A., Johnson B., Amber I.J., Callahan K.S., Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 77:1996;723-727.
22. Aukrust P., Ueland T., Lien E., Klaus B., Muller F., Andreassen A.K., Ingvild N., Aass H., Espevik T., Simonsen S., Froland S.S., Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 83:1999;376-382.
23. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 27:1996;1201-1206.
24. Carlstedt F., Lind L., Lindahl B. Proinflammatory cytokines measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med. 242:1997;361-365.
25. Roig E., Orus J., Pare C., Azqueta M., Filella X., Perez-Villa F., Heras M., Sanz G. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 82:1998;688-690.
26. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., Mabuchi N., Sawaki M., Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 31:1998;391-398.
27. Anker S.D., Clark A.L., Teixeira M.M., Hellewell P.G., Coats A.J. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 83:1999;612-615.
28. Mann D.L. Stress activated cytokines and the heart. Cytokine Growth Factor Rev. 7:1996;341-354.
29. Bevilacqua M.P., Nelson R.M., Mannori G., Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 45:1994;361-378.
30. Jang Y., Lincoff M., Plow E., Topol E.J. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 24:1994;1591-1601.
31. Labarrere C.Y., Pitts D., Nelson D.R., Faulk W.P. Association of arterial intercellular adhesion molecule-1 (ICAM-1 or CD54) with development of coronary heart disease in transplanted human hearts. Transplantation Medizin. 7:1995;144-148.
32. Verrier E.D., Shen I. Potential role of neutrophil antiadhesion therapy in myocardial infarction and organ dysfunction after cardiopulmonary bypass. J Cardiac Surg. 8:1993;309-312.
33. Devaux B., Scholz D., Hirche A., Klovekorn W.P., Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 18:1997;470-479.
34. Pober J.S., Cotran R.S. The role of endothelial cells in inflammation. Transplantation. 50:1990;537-544.
35. Tsutamoto T., Hisanaga T., Fukai D., Wada A., Maeda Y., Kinoshita M. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 76:1995;803-808.
36. Gearing A.J., Newman W. Circulating adhesion molecules in disease. Immunol Today. 14:1993;506-512.
37. Andreassen A.K., Nordoy I., Simonsen S., Ueland T., Muller F., Froland S.S., Gullestad L., Aukrust P. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 81:1998;604-608.
38. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., Billingham M.E., Harrison D.C., Stinson E.B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 307:1982;205-211.
39. Merlet P., Valette H., Dubois-Rande J.L., Moyse D., Duboc D., Dove P., Bourguignon M.H., Benvenuti C., Duval A.M., Agostini D. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 33:1992;471-477.
40. Jahns R., Boivin V., Siehmund C., Inselmann G., Lohse M.J., Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 99:1999;649-654.
41. Hwang S., Harris T.J., Wilson N.W., Maisel A.S. Immune function in patients with chronic stable congestive heart failure. Am Heart J. 125:1993;1651-1658.
42. Dorffel W.V., Felix S.B., Wallukat G., Brehme S., Bestvater K., Hofmann T., Kleber F.X., Baumann G., Reinke P. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation. 95:1997;1994-1997.
43. Bilinska Z., Caforio A., Kusmierczyk-Droszcz B., Michalak E., Grzybowski J., Goldman J., Haven A., Rydlewska-Sadowska W., McKenna W., Ruzyooo W. Increased frequency of organ-specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: evidence for autoimmunity in Polish families. Clin Cardiol. 19:1996;794-798.
44. Mestroni L., Rocco C., Gregori D., Sinagra G., Di Lenarda A., Miocic S., Vatta M., Pinamonti B., Muntoni F., Caforio A., McKenna W., Falaschi A., Giacca M., Camerini. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol. 34:1999;181-190.
45. Huber S.A. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol. 83:1997;93-102.
46. Kishimoto C., Abelmann W. In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury. Circ Res. 67:1990;589-598.
47. Huber K.C., Gersh B.J., Sugrue D.D., Frye R.L., Bailey K.R., Ritts R.E. T-lymphocyte subsets in patients with idiopathic dilated cardiomyopathy. Int J Cardiol. 22:1989;59-66.
48. Kanda T., Yokoyama T., Ohshima S., Yuasa K., Watanabe T., Suzuki T., Murata K. T-lymphocyte subsets as noninvasive markers of cardiomyopathy. Clin Cardiol. 13:1990;617-622.
49. Mailhos C., Howard M.K., Latchman D.S. Heat shock proteins hsp 90 and hsp 70 protect neuronal cells from thermal stress but not from programmed cell death. J Neurochem. 63:1994;1787-1795.
50. Knowlton A.A., Kapadia S., Torre-Amione G., Durand J.B., Bies R., Young J., Mann D.L. Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol. 30:1998;811-818.
51. Singal P.K., Khaper N., Palace V., Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res. 40:1998;426-432.
52. Ferrari R., Agnoletti L., Comini L., Gaia G., Bachetti T., Cargnoni A., Ceconi C., Curello S., Visioli O. Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J. 19:1998;B2-B11.
53. Rimm E.B., Ascherio A., Giovannucci E., Spiegelman D., Stampfer M.J., Willett W.C. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. J Am Med Assoc. 275:1996;447-451.
54. Jha P., Flather M., Lonn E., Farkouh M., Yusuf S. The antioxidant vitamins (E, C and beta-carotene) and cardiovascular disease: a critical summary of epidemiological and clinical trial data. Ann Intern Med. 123:1995;860-872.
55. Lonn E.M., Yusuf S. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol. 13:1997;957-965.
56. Ruffolo R.R.J., Feuerstein G.Z. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 32:1998;S22-S30.
57. Mendez C., Garcia I., Maier R. Oxidants augment endotoxin-induced activation of alveolar macrophages. Shock. 6:1996;157-163.
58. Anker S.D., Egerer K.R., Volk H.D., Kox W.J., Poole-Wilson P.A., Coats A.J. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 79:1997;1426-1430.
59. Niebauer J., Volk H.-D., Kemp M., Dominguez M., Schumann R., Rauchhaus M., Poole-Wilson P., Coats A., Anker S. Endotoxin and immune activation in chronic heart failure. Lancet. 353:1999;1838-1842.
60. Haque R., Kan H., Finkel M.S. Effects of cytokines and nitric oxide on myocardial E-C coupling. Basic Res Cardiol. 93:1998;86-94.
61. Nishiyama Y., Ikeda H., Haramaki N., Yoshida N., Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J. 135:1998;115-120.
62. Leyva F., Anker S.D., Godsland I.F., Teixeira M., Hellewell P.G., Kox W.J., Poole-Wilson P.A., Coats A.J. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 19:1998;1814-1822.
63. Leyva F., Chua T.P., Anker S.D., Coats A.J. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism. 47:1998;1156-1159.
64. Leyva F., Anker S.D., Swan J.W., Godsland I.F., Wingrove C.S., Chua T.P., Stevenson J.C., Coats A.J. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 18:1997;858-865.
65. Anker S.D., Leyva F., Poole-Wilson P.A., Kox W.J., Stevenson J.C., Coats A.J. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 78:1997;39-43.
66. Sluiter W., Pietersma A., Lamers J.M., Korster J.F. Leukocyte adhesion molecules and the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol. 22:1993;S37-S44.
67. Ashraf M., Samra Z.Q. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. J Submicrosc Cytol Pathol. 25:1993;293-301.
68. Zweier J.L., Kuppusamy P., Lutty G.A. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in post-ischemic tissues. Proc Natl Acad Sci USA. 85:1988;4046-4050.
69. Terada L.S., Guidot D.M., Leff J.A., Willingham I.R., Hanley M.E., Piermattei D., Repine J.E. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci USA. 89:1992;3362-3366.
70. Lazzarino G., Raatikainen P., Nuutinen M., Nissinen J., Tavazzi B., Di Pierro D., Giardina B., Peuhkurinen K. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation. 90:1994;291-297.
71. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 98:1996;2572-2579.
72. Granger D.N., Benoit J.N., Suzuki M., Grisham M.B. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol. 257:1989;G683-G688.
73. Menger M.D., Peikan S., Ateiner D., Messmer K. Microvascular ischemia-reperfusion injury in striated muscle: significance of 'reflow paradox'. Am J Physiol. 263:1992;H1901-H1906.
74. Farquharson C., Butler R., Struthers A. Allopurinol improves endothelial dysfunction in patients with chronic heart failure. J Am Coll Cardiol. 216A:1999;895(1). (Abstract).
75. Li P.F., Dietz R., von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. FEBS Lett. 448:1999;206-210.
76. Schalcher C., Brunner H.P., Oechslin E. Endothelial control of vascular tone in chronic heart failure. J Cardiovasc Pharmacol. 32:1998;S67-73.
77. Drexler H., Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 31:1999;51-60.
78. Vanderheyden M., Kersschot E., Paulus W.J. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. Eur Heart J. 19:1998;747-752.
79. Zelis R., Flaim S.F. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis. 24:1982;437-459.
80. Balligand J.L., Ungureanu-Longrois D., Simmons W.W., Pimental D., Malinski T.A., Kapturczak M., Taha Z., Lowenstein C.J., Davidoff A.J., Kelly R.A., Smith T.W., Michel T. Cytokine-inducible nitric oxide synthase expression in cardiac myocytes. J Biol Chem. 269:1994;580-588.
81. Sawyer D.B., Colucci W.S. Nitric oxide in the failing myocardium. Cardiol Clin. 16:1998;657-664.
82. Vejlstrup N.G., Bouloumie A., Boesgarrd S., Andersen C.B., Nielsen-Kudsk J.E., Mortensen S.A., Kent J.D., Harrison D.G., Busse R., Aldershvile J. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 30:1998;1215-1223.
83. Hare J.M., Givertz M.M.C.M.A., Colucci W.S. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation. 97:1998;161-166.
84. Shindo T., Ikeda U., Ohkawa F., Kawahara Y., Yokoyama M., Shimada K. Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res. 29:1995;813-819.
85. Albina J.E., Cui S., Mateo R.B., Rerichner J.S. Nitric-oxide mediated apoptosis in murine peritoneal macrophages. J Immunol. 150:1993;5080-5085.
86. Pulkki K.J. Cytokines and cardiomyocyte death. Ann Med. 29:1997;339-343.
87. Flesch M., Kilter H., Cremers B., Laufs U., Sudkamp M., Ortmann M., Muller F.U., Bohm M. Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. J Am Coll Cardiol. 33:1999;1062-1070.
88. Hambrecht R., Adams V., Gielen S., Linke A., Mobius-Winkler S., Yu J., Niebauer J., Jiang H., Fiehn E., Schuler G. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 33:1999;174-179.
89. Anker S.D., Volterrani M., Egerer K.R., Felton C.V., Kox W.J., Poole-Wilson P.A., Coats A.J. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM. 91:1998;199-203.
90. Adachi H., Nguyen P.H., Belardinelli R., Hunter D., Jung T., Wasserman K. Nitric oxide production during exercise in chronic heart failure. Am Heart J. 134:1997;196-202.
91. Haynes W.G., Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 16:1998;1081-1098.
92. Ruetten H., Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamathasone. J Physiol Pharmacol. 48:1997;675-688.
93. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., Heublin D.M., Kao P.C., Edwards W.D., Burnett J.C. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
94. Yousufuddin M, Shamim W, Chambers J, Henein M, Amin F, Anker S, Kemp M, Hooper J, Coats A. Superiority of endothelin-1 over norepinephrine in exercise-induced alterations of the conduit artery tone of the nonexercised arm in patients with chronic heart failure. Int J Cardiol 1999:in press.
95. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 23:1994;1427-1433.
96. Sakai S., Miyauchi T., Sakurai T., Yamaguchi I., Kobayashi M., Goto K., Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol. 28:1996;1580-1588.
97. Kiowski W., Sutsch G., Hunziker P., Muller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
98. Roux S., Breu V., Ertel S., Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med. 77:1999;364-376.
99. Kapadia S.R., Oral H., Lee J., Nakano M., Taffet G.E., Mann D.L. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 81:1997;187-195.
100. Moore K., O'Garra A., de Wall Malefyt R., Vieria P., Mosmann T. Interleukin-10. Ann Rev Immunol. 11:1993;165-171.
101. Kirchengast M., Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 221:1999;312-325.
102. Kapadia S., Lee J., Torre-Amione G., Birdsall H.H., Ma T.S., Mann D.L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 96:1995;1042-1052.
103. Vonhof S., Brost B., Stille-Siegener M., Grumbach I., Kreuzer H., Figulla H. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol. 63:1998;237-244.
104. Hasper D., Hummel M., Kleber F.X., Reindl I., Volk H.D. Systemic inflammation in patients with heart failure. Eur Heart J. 19:1998;761-765.
105. Anker S. Catecholamine levels and treatment in chronic heart failure. Eur Heart J. 19:1998;F56-F61.
106. Drexler H., Kurz S., Jeserich M., Munzel T., Hornig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol. 76:1995;13E-18E.
107. Hornig B., Arakawa N., Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J. 19:1998;G48-G53.
108. Walter M., Liebens I., Goethals H., et al. Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol. 25:1988;323-329.
109. Renard M., Walter M., Liebens I., et al. Pimobendan (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest. 93:1988;1159-1164.
110. Hagemeijer F., Brand H.J., Roth W. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol. 14:1989;302-310.
111. Sasayama S., Matsumori A., Matoba Y., Matsui S., Yamada T., Shioi T., Sato Y., Doyama K., Kishimoto C. Immunomodulation: a new horizon for medical treatment of heart failure. J Card Fail. 2:1996;S287-S294.
112. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955-958.
113. Matsumori A., Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy-lessons from animal experiments. Eur Heart J. 16:1995;140-143.
114. Iwasaki A., Matsumori A., Yamada T., Shioi T., Wang W., Ono K., Nishio R., Okada M., Sasayama S. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol. 33:1999;1400-1407.
115. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093.
116. Goldenburg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 21:1999;75-87.
117. Moreland L.W. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol. 26:1999;7-15.
118. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 340:1999;1398-1405.
119. Bozkurt B., Kribbs S., Clubb F. Jr., Michael L., Didenko V., Hornsby P., Seta Y., Oral H., Spinale F., Mann D. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
120. Kapadia S., Torre-Amione G., Yokoyama T., Mann D.L. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol. 268:1995;H517-H525.
121. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F., Blosch C., Mann D. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 99:1999;3224-3226.